Adaption of regulatory statement on Product Quality Certificates and Certificates of Analysis

<table>
<thead>
<tr>
<th>Product</th>
<th>Regulatory Status</th>
<th>Material No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>MACS® GMP T Cell TransAct™ CRR</td>
<td>CRR-US</td>
<td>200-076-202</td>
</tr>
<tr>
<td>CliniMACS® PBS/EDTA Buffer 1L</td>
<td>HUD</td>
<td>200-070-026</td>
</tr>
<tr>
<td>MACS® GMP ExpAct Treg Kit</td>
<td>CRR-US</td>
<td>200-070-412</td>
</tr>
<tr>
<td>CliniMACS® CD34 Reagent</td>
<td>HUD</td>
<td>200-070-103</td>
</tr>
<tr>
<td>CliniMACS® CD34 GMP MicroBeads</td>
<td>MACS GMP</td>
<td>170-076-711</td>
</tr>
</tbody>
</table>

Category of change: Change of Product Quality Certificates and Certificates of Analysis

Current State: A Product Quality Certificate (PCQ) or a Certificate of Analysis (CoA) is issued for each product lot of above mentioned products.

1. Following is stated on the CoA/PQC of the CliniMACS PBS/EDTA Buffer 1L HUD and CliniMACS CD34 Reagent HUD:
   “We hereby certify that the above information is authentic and accurate. This batch of product has been manufactured, including packaging and quality control, in full compliance with the GMP requirements under an ISO 13485 Quality System according to in-house specifications. The batch processing, packaging, and analysis records were reviewed and found to be in compliance with GMP.”

2. Following is stated on the PQC/CoA of the MACS GMP T Cell TransAct, CRR-US and MACS GMP ExpAct Treg Kit, CRR-US:
   “Compliance statement Caution: Clinical Research Reagent, Limited by Federal (or United States) Law to Investigational Use.”

3. The PQC/CoA of CliniMACS CD34 GMP MicroBeads indicate Endotoxin and Sterility testing only.

Planned change: The Certificates of Analysis and Product Quality Certificates will be revised. Thereby, following changes will be implemented:

1. Compliance Statement on CliniMACS CD34, HUD and CliniMACS PBS/EDTA Buffer 1L, HUD will indicate:
   “HUMANITARIAN DEVICE: Authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated.”
Adaption of regulatory statement on Product Quality Certificates and Certificates of Analysis

CAUTION: Federal law restricts this device to sale by or on the order of a physician. We hereby certify that the above information is authentic and accurate. This batch of product has been manufactured, including packaging and quality control, in full compliance with the GMP requirements under an ISO 13485 Quality System according to in-house specifications. The batch processing, packaging, and analysis records were reviewed and found to be in compliance with GMPs.

2. Compliance Statement on MACS GMP T Cell TransAct, CRR and MACS GMP ExpAct Treg Kit, CRR will indicate: “Compliance statement Caution: Clinical Research Reagent, Limited by Federal (or United States) Law to Investigational Use or under FDA approval.”

3. Following tests will be added to the CliniMACS CD34 GMP MicroBeads certificates: OD450, Free Dextran and biological performance (CD34 Selection Assay).

All remaining Certificates of Analysis will be replaced by the Product Quality Certificate by this change.

Justification/Evaluation: There is an update on regulatory statement only. This update will increase clarity regarding the use of CRR products with FDA approval.

There is no change of raw material or manufacturing process. Therefore no impact on the performance, quality and safety of the affected product could be identified.

Estimated Implementation Q2/2021

Please share, if applicable, this information with relevant staff in your organization. If there are any further questions, do not hesitate to contact us.

Manager QA Audit/Customer/Supplier
Miltenyi Biotec B.V. & Co.KG